Market Closed -
Euronext Paris
11:35:29 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
1.97
EUR
|
+3.79%
|
|
+1.76%
|
-44.59%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
142.4
|
237
|
895.3
|
332.2
|
100.6
|
100.6
|
-
|
Enterprise Value (EV)
1 |
142.4
|
237
|
895.3
|
332.2
|
100.6
|
100.6
|
100.6
|
P/E ratio
|
-
|
-
|
-
|
-24.4
x
|
-5.18
x
|
-5.47
x
|
-5.32
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
83.7
x
|
151
x
|
566
x
|
-
|
108
x
|
102
x
|
91.5
x
|
EV / Revenue
|
83.7
x
|
151
x
|
566
x
|
-
|
108
x
|
102
x
|
91.5
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-5.27
x
|
-5.62
x
|
-5.36
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-5.35
x
|
-5.59
x
|
-5.29
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-18.7%
|
-17.9%
|
-18.9%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,064
|
44,060
|
45,540
|
46,861
|
51,067
|
51,067
|
-
|
Reference price
2 |
3.468
|
5.380
|
19.66
|
7.090
|
1.970
|
1.970
|
1.970
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/30/21
|
3/1/23
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
1.701
|
1.571
|
1.583
|
-
|
0.93
|
0.99
|
1.1
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-19.1
|
-17.89
|
-18.78
|
EBIT
1 |
-
|
-17.47
|
-
|
-
|
-15.96
|
-15.91
|
-15.8
|
Operating Margin
|
-
|
-1,112.29%
|
-
|
-
|
-1,716.13%
|
-1,607.07%
|
-1,436.36%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
-
|
-
|
-13.62
|
-19.64
|
-18.77
|
-18
|
Net margin
|
-
|
-
|
-
|
-
|
-2,111.83%
|
-1,895.96%
|
-1,636.36%
|
EPS
2 |
-
|
-
|
-
|
-0.2900
|
-0.3800
|
-0.3600
|
-0.3700
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-18.81
|
-17.99
|
-19
|
FCF margin
|
-
|
-
|
-
|
-
|
-2,022.58%
|
-1,817.17%
|
-1,727.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/30/21
|
3/1/23
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-18.8
|
-18
|
-19
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.48
|
-
|
-
|
-
|
0.05
|
0.06
|
0.5
|
Capex / Sales
|
28.45%
|
-
|
-
|
-
|
5.38%
|
6.06%
|
45.45%
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/30/21
|
3/1/23
|
-
|
-
|
-
|
Last Close Price
1.97
EUR Average target price
6.895
EUR Spread / Average Target +250.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -44.59% | 108M | | +5.48% | 71.19B | | +12.55% | 9.3B | | -13.75% | 5.01B | | +42.38% | 4.47B | | +4.51% | 3.96B | | +21.10% | 2.44B | | -19.05% | 2.41B | | -28.72% | 2.23B | | +11.13% | 2.02B |
Specialty & Advanced Pharmaceuticals
|